Skip to main content
. 2021 Aug 9;2021:1412663. doi: 10.1155/2021/1412663

Table 2.

Factors associated with change in disease behavior

All B1 patients (n = 87) (L2 + L3) in B1 patients (n = 71)
Univariate Multivariate Univariate Multivariate
P HR (95%CI) P HR (95%CI) P HR (95%CI) P HR (95%CI)
Female 0.387 0.75 (0.39–1.45) NS 0.418 0.73 (0.35–1.55) NS
Smoking
 Former vs. never 0.974 NA NS 0.984 NA NA
 Current vs. never 0.736 1.13 (0.55–2.34) NS 0.796 0.90 (0.40–2.01) NS
Age at diagnosis
A2 vs. A1 0.246 2.03 (0.61–6.72) NS 0.224 2.45 (0.58–10.37) NS
A3 vs. A1 0.199 2.36 (0.64–8.74) NS 0.284 2.46 (0.47–12.74) NS
Location at diagnosis
L2 vs. L1 0.360 1.53 (0.61–3.82) NS NA NA
L3 vs. L1 0.931 1.04 (0.39–2.80) NS NA NA
L4 involvement 0.866 1.08 (0.42–2.78) NS 0.894 0.93 (0.33–2.66) NS
Perianal disease 0.398 1.68 (0.51–5.57) NS 0.241 2.07 (0.62–6.96) NS
Appendicectomy 0.007 0.27 (0.11–0.70) 0.018 0.32 (0.12–0.82) 0.022 0.33 (0.13–0.85) 0.013 0.30 (0.11–0.78)
Elevated ESR at diagnosis 0.559 1.22 (0.63–2.33) NS 0.172 1.65 (0.80–3.38) NS
CDAI at diagnosis 0.180 1.00 (1.00–1.01) NS 0.115 1.00 (1.00–1.01) NS
5-Aminosalicylic acid ≤0.001 0.29 (0.15–0.55) 0.001 0.29 (0.14–0.58) 0.002 0.32 (0.16–0.66) 0.001 0.30 (0.14–0.61)
Corticosteroid 0.140 0.60 (0.31–1.18) NS 0.633 0.84 (0.42–1.71) NS
Immunomodulators 0.085 0.52 (0.25–1.10) 0.854 0.93 (0.41–2.11) 0.179 0.59 (0.27–1.28) NS
Biologics 0.037 0.43 (0.20–0.95) 0.075 0.47 (0.21–1.08) 0.130 0.54 (0.24–1.20) NS

HR, hazard ratio; ESR, erythrocyte sedimentation rate; NA, not available; NS, not significance (P > 0.10) in the univariate Cox regression; CDAI: Crohn's disease activity index.